<DOC>
	<DOCNO>NCT00437216</DOCNO>
	<brief_summary>Evaluation effectiveness Clobex® Spray , 0.05 % use monotherapy add-on therapy exist systemic topical anti-psoriatic agent .</brief_summary>
	<brief_title>Efficacy , Tolerance Satisfaction With CLOBEX® Spray When Used Monotherapy Add-on Therapy Plaque Psoriasis</brief_title>
	<detailed_description>Evaluation effectiveness Clobex® Spray , 0.05 % use monotherapy add-on therapy exist systemic topical anti-psoriatic agent , determine change target plaque severity ( TPS ) rating Weeks 0 4 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Moderate severe plaque psoriasis 3 % 20 % Body Surface Area ( BSA ) target plaque severity ( TPS ) moderate severe At least 1 target site ( palms sol foot ) TPS rating moderate severe 1 elevate , easily palpable , plaque wellcircumscribed margin , least 1 cm diameter History stable plaque psoriasis great equal 3 month Diagnosis guttate , generalize pustular , erythrodermic , psoriatic arthritis , nail psoriasis sole predominant form psoriasis Psoriatic arthritis stable might require change medication 4week study period Plaque psoriasis require treatment face , scalp , neck , groin , armpit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>